The Hypophosphatasia drugs in development market research report provides comprehensive information on the therapeutics under development for Hypophosphatasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypophosphatasia. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Hypophosphatasia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypophosphatasia and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Hypophosphatasia by seven companies/universities/institutes. The top development phase for Hypophosphatasia is preclinical with five drugs in that stage. The Hypophosphatasia pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Hypophosphatasia pipeline products market are: Alexion Pharmaceuticals, Am-Pharma and Rallybio.

The key targets in the Hypophosphatasia pipeline products market include Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1), Alkaline Phosphatase Tissue Nonspecific Isozyme (Alkaline Phosphatase Liver/Bone/Kidney Isozyme or TNAP or ALPL or EC 3.1.3.1), and Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1 (Membrane Component Chromosome 6 Surface Marker 1 or Phosphodiesterase I/Nucleotide Pyrophosphatase 1 or Plasma Cell Membrane Glycoprotein PC1 or ENPP1 or EC 3.1.4.1 or EC 3.6.1.9).

The key mechanisms of action in the Hypophosphatasia pipeline product include Alkaline Phosphatase (ALKP or Phosphomonoesterase or Glycerophosphatase or Alkaline Phosphohydrolase or EC 3.1.3.1) Replacement with three drugs in Phase II. The Hypophosphatasia pipeline products include three routes of administration with the top ROA being Intravenous and five key molecule types in the Hypophosphatasia pipeline products market including Gene Therapy, and Recombinant Enzyme.

Hypophosphatasia overview

Hypophosphatasia (HOPS) is a rare inherited disorder characterized by the deficiency of alkaline phosphatase. It is also referred as phosphoethanolaminuria or Rathbun disease. HOPS is caused by mutations in the ALPL gene, which is responsible for making tissue non-specific alkaline phosphatase (TNSALP). ALP plays an important role in the mineralization of the skeleton and teeth. HOPS weakens and softens the bones, resulting in the skeletal abnormalities. Affected infants are born with short limbs, an abnormally shaped chest, and soft skull bones. The forms of hypophosphatasia that appear in childhood or adulthood are typically less severe than those that appear in infancy.

For a complete picture of Hypophosphatasia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.